Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference.
The company's President and CEO, Jeffrey Stein, Ph.D., will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 PM ET. The presentation will be available via webcast and can be accessed through a provided link. A replay will be accessible in the Investors section of Cidara's website for 90 days following the event.
Additionally, Cidara will conduct one-on-one investor meetings during the conference. Interested investors should contact their Guggenheim representative to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CDTX gained 2.62%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Details are as follows:
Event: Guggenheim Securities SMID Cap Biotech Conference
Date: Wednesday, February 5, 2025
Time: 1:30 PM ET
Format: Fireside chat
Webcast: https://wsw.com/webcast/guggen2/cdtx/2014749
A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Guggenheim representative directly.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors access CDTX's Guggenheim Conference presentation webcast?
How long will CDTX's Guggenheim Conference presentation replay be available?
What type of presentation format will CDTX deliver at the Guggenheim Biotech Conference?
How can investors arrange one-on-one meetings with CDTX at the Guggenheim Conference?
